Intra-Cellular Therapies (ITCI) Misses Q4 EPS by 2c

Note: EPS may not be comparable

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.56), $0.02 worse than the analyst estimate of ($0.54).

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Helius Medical Technologies (HSDT) Misses Q2 EPS by 31c
• Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c